Phase 1/2a Trial of NWRD09 for Persistent HPV16 Infection in Female Participants
ClinicalTrials.gov Studies
Summary
The NIH ClinicalTrials.gov registry has posted a new Phase 1/2a clinical trial (NCT07536282) evaluating NWRD09, an investigational drug, for the treatment of persistent HPV16 infection in female participants. The two-part study will assess safety, tolerability, immunogenicity, and efficacy while determining the maximum tolerated dose and recommended Phase 2 dose. Participants will receive either NWRD09 or placebo as part of the study design.
What changed
The NIH ClinicalTrials.gov registry has added a new Phase 1/2a clinical trial (NCT07536282) titled 'Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection.' The trial is designed as a two-part study to evaluate the safety, tolerability, immunogenicity, and efficacy of NWRD09, an investigational drug candidate, in female participants diagnosed with persistent HPV16 infection. The study will also determine the maximum tolerated dose and/or recommended Phase 2 dose of the intervention.
For pharmaceutical companies and clinical investigators, this trial represents an active clinical development program for an HPV16 treatment candidate. Trial sponsors developing competing or complementary HPV therapeutics should monitor enrollment and preliminary outcomes. Clinical investigators specializing in infectious disease or women's health may consider collaboration or competing trial opportunities in this therapeutic space.
Archived snapshot
Apr 18, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection
Phase 1 NCT07536282 Kind: PHASE1 Apr 17, 2026
Abstract
This is a two-part, phase I/IIa study, intended to evaluate the safety, tolerability, immunogenicity, and efficacy of NWRD09 in female participants with persistent HPV16 infection, and to determine the MTD, and/or RP2D of NWRD09.
Conditions: Persistent HPV16 Infection
Interventions: NWRD09, Placebo
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.